JP2010514725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514725A5 JP2010514725A5 JP2009543441A JP2009543441A JP2010514725A5 JP 2010514725 A5 JP2010514725 A5 JP 2010514725A5 JP 2009543441 A JP2009543441 A JP 2009543441A JP 2009543441 A JP2009543441 A JP 2009543441A JP 2010514725 A5 JP2010514725 A5 JP 2010514725A5
- Authority
- JP
- Japan
- Prior art keywords
- methanone
- methanesulfonyl
- trifluoro
- trifluoromethyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3- Fluoro-5-trifluoromethyl-pyridin-2-yl Chemical group 0.000 claims 21
- 239000013078 crystal Substances 0.000 claims 12
- 238000002441 X-ray diffraction Methods 0.000 claims 6
- 238000002329 infrared spectrum Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- YUUGYIUSCYNSQR-LBPRGKRZSA-N [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2s)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone Chemical compound FC(F)(F)[C@H](C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2C(=CC(=CN=2)C(F)(F)F)F)CC1 YUUGYIUSCYNSQR-LBPRGKRZSA-N 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- GWTMPNXPVMDUTM-UHFFFAOYSA-N 3-fluoro-5-(trifluoromethyl)pyridine Chemical compound FC1=CN=CC(C(F)(F)F)=C1 GWTMPNXPVMDUTM-UHFFFAOYSA-N 0.000 claims 1
- VFDFJCYNWDITDA-ZETCQYMHSA-N 5-methylsulfonyl-2-[(2s)-1,1,1-trifluoropropan-2-yl]oxybenzaldehyde Chemical compound FC(F)(F)[C@H](C)OC1=CC=C(S(C)(=O)=O)C=C1C=O VFDFJCYNWDITDA-ZETCQYMHSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127269.6 | 2006-12-28 | ||
| EP06127269 | 2006-12-28 | ||
| PCT/EP2007/064104 WO2008080821A1 (en) | 2006-12-28 | 2007-12-18 | Crystalline forms glyt1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514725A JP2010514725A (ja) | 2010-05-06 |
| JP2010514725A5 true JP2010514725A5 (https=) | 2010-12-02 |
| JP4799666B2 JP4799666B2 (ja) | 2011-10-26 |
Family
ID=38988312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543441A Active JP4799666B2 (ja) | 2006-12-28 | 2007-12-18 | 結晶形態のｇｌｙｔ１ |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US20080214561A1 (https=) |
| EP (1) | EP2114405B1 (https=) |
| JP (1) | JP4799666B2 (https=) |
| KR (1) | KR101130146B1 (https=) |
| CN (1) | CN101573114A (https=) |
| AR (1) | AR064545A1 (https=) |
| AU (1) | AU2007341356B2 (https=) |
| BR (1) | BRPI0720829B8 (https=) |
| CA (1) | CA2673667A1 (https=) |
| CL (1) | CL2007003830A1 (https=) |
| CO (1) | CO6190613A2 (https=) |
| CR (1) | CR10846A (https=) |
| CY (1) | CY1116350T1 (https=) |
| DK (1) | DK2114405T3 (https=) |
| EC (1) | ECSP099471A (https=) |
| ES (1) | ES2535040T3 (https=) |
| HR (1) | HRP20150573T1 (https=) |
| HU (1) | HUE025032T2 (https=) |
| MA (1) | MA31029B1 (https=) |
| MX (1) | MX2009006859A (https=) |
| MY (1) | MY188367A (https=) |
| NO (1) | NO342150B1 (https=) |
| NZ (1) | NZ577502A (https=) |
| PE (1) | PE20081556A1 (https=) |
| PL (1) | PL2114405T3 (https=) |
| PT (1) | PT2114405E (https=) |
| RS (1) | RS53910B1 (https=) |
| RU (1) | RU2463295C2 (https=) |
| SI (1) | SI2114405T1 (https=) |
| TW (1) | TWI388552B (https=) |
| UA (1) | UA100232C2 (https=) |
| WO (1) | WO2008080821A1 (https=) |
| ZA (1) | ZA200904423B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009006859A (es) | 2006-12-28 | 2009-07-03 | Hoffmann La Roche | Formas cristalinas de glyt1. |
| JP6074142B2 (ja) * | 2009-02-26 | 2017-02-01 | タール ファーマシューティカルズ，インコーポレイテッド | 医薬化合物の結晶化 |
| KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
| CN104334550A (zh) * | 2012-05-25 | 2015-02-04 | 巴斯夫欧洲公司 | 1,5-二甲基-6-硫代-3-(2,2,7-三氟-3-氧代-4-(丙-2-炔基)-3,4-二氢-2H-苯并[b][1,4]噁嗪-6-基)-1,3,5-三嗪烷-2,4-二酮的晶型B |
| US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
| MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| JP7096956B2 (ja) * | 2020-07-13 | 2022-07-06 | 日本碍子株式会社 | 精製方法 |
| EP4337199A4 (en) * | 2021-05-14 | 2025-03-19 | Disc Medicine, Inc. | Methods for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibition agents |
| CN118043050A (zh) * | 2021-05-27 | 2024-05-14 | 迪斯克医药公司 | 用固体形式的比托哌汀治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| RS53252B (sr) * | 2003-08-11 | 2014-08-29 | F.Hoffmann-La Roche Ag. | Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| MX2009006859A (es) | 2006-12-28 | 2009-07-03 | Hoffmann La Roche | Formas cristalinas de glyt1. |
-
2007
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 RS RS20150229A patent/RS53910B1/sr unknown
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en not_active Ceased
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 HR HRP20150573TT patent/HRP20150573T1/hr unknown
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active Active
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514725A5 (https=) | ||
| JP2011513485A5 (https=) | ||
| RU2009124113A (ru) | Кристаллические формы glyt1 | |
| JP2009040783A5 (https=) | ||
| ES2351958T3 (es) | 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-[2,3'] bipiridinil en forma cristalina pura y procedimiento de síntesis. | |
| HRP20231533T1 (hr) | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave | |
| ME02747B (me) | Kristalni oblik gama ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže | |
| JP2020536893A5 (https=) | ||
| JP2009534373A5 (https=) | ||
| PT2651890E (pt) | Derivados de estrigolactama e sua utilização como reguladores do crescimento das plantas | |
| JP2014510133A (ja) | １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法 | |
| JP2018531280A5 (https=) | ||
| JP2020502224A5 (https=) | ||
| JP2005520819A5 (https=) | ||
| JP2016510768A5 (https=) | ||
| JP2019516749A5 (https=) | ||
| EP3337485A1 (en) | Crystalline forms of ibrutinib | |
| JP2016539136A5 (https=) | ||
| JP2007519697A5 (https=) | ||
| RU2018103172A (ru) | Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона | |
| JP2005529084A5 (https=) | ||
| RU2012136148A (ru) | Новая кристаллическая форма производного циклопропилбензамида | |
| JP2022535870A (ja) | Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途 | |
| JP2020138960A5 (https=) | ||
| WO2005085199A1 (en) | Novel polymorphs of etoricoxib |